谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Efficacy and Safety of Camrelizumab Plus Apatinib in Patients with Advanced Esophageal Squamous Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors (CAP 02 Re-challenge): a Single-Arm, Phase II Study

Xiangrui Meng,Junsheng Wang,Jin Xia,Tao Wu,Zhiquan Luo,Yonggui Hong,Ping Lu,Yanzhen Guo,Yinghua Ji,Min Zhang,Liuzhong Yang, Peng Cheng,Wenchang Liang,Zhengzheng Shan,Yue Zhou,Mingyue Wang,Taiying Lu, Min Song,Hong Zong,Lijie Song, Wenkang Wang,Lulu Guan, Yanke Li, Jianxiang Xing, Siyuan Xing, Han Wu, Jingwen Chu,Xi Luo,Yao Lu,Dao Xin, Aijia Li, Binghua Jiang, Shenglei Li, Guozhong Jiang,Qingxia Fan, Feng Zhao,Rongrong Zheng, Wenqing Zhu, Zhiguo Hou, Yun Jia,Feng Wang

European journal of cancer (Oxford, England 1990)（2024）

引用 0|浏览7
暂无评分
关键词
Esophageal squamous cell carcinoma,Immune checkpoints inhibitors,Re-challenge,Camrelizumab plus apatinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要